Conversation

Yes, though I still think it’s very unlikely for you and me. More relevant is my shifted expectation for the broader Kaplan-Meier curve. eg I was quite shocked to learn how rapidly cell senescence clearance went from first intervention (‘13) to an IPO (literally today: Unity)
1
I was excited about the experimentation platform. And I liked Circumvent Pharma's approach of targeting an accelerated form of a broader range of neurodegenerative diseases as a test-bed. And of course, Age 1 itself pressures the culture to be more rapid.
1